Clostridium Infections Clinical Trial
Official title:
MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation
The registry collects cases of patients received fecal microbiota transplantation (FMT) due to Clostridium difficile associated diarrhea (CDAD). The main objective of this study is to analyze the safety and effectiveness of FMT. Furthermore, data analysis will be used to implement a standardization of FMT in German hospitals and improve patient outcome. Therefore, a detailed description of completions of FMT are documented on our web-based survey platform www.ClinicalSurveys.net.
Concerning the documentation of patients received fecal microbiota transplantation (FMT) due
to Clostridium difficile associated diarrhea (CDAD), physicians from all German hospitals
performing a FMT are invited to provide prospective and retrospective information on these
cases. Documentation of patient is performed by using the web-based survey platform
www.ClinicalSurveys.net which was set up by researchers of the University Hospital of
Cologne. This survey platform enables an optimal performance in epidemiological,
observational, and interventional trials and is characterized by layered access security and
frequent data backup. It has been used for numerous registry and cohort studies with
approval of competent authorities and ethics boards.
The following data items are retrospectively or prospectively documented into our database,
depending on if a informed consent exists or not:
- Patient characteristics (age, gender, weight, height, underlying disease)
- Indication for FMT
- Administration of antibiotics, chemotherapy, and immunosuppression prior to FMT
- Bowel movement prior to FMT
- Screening prior to FMT
- Description concerning completion of FMT
- Basic informations of the donor
- Outcome
- Prospective long term follow up (10 days, four weeks, three months, six months, and 24
months)
The following two differences of data documentation are observed:
1. Retrospective data documentation:
Data of patients without an informed consent are documented strictly retrospectively
after completion of the FMT. No pseudonymization of patient data is carried out so that
no re-identification is possible.
2. Prospective data documentation:
Data of patients with an informed consent prior to FMT are documented prospectively. A
pseudonymization of patient data allows a post-FMT contact (by writing or phone) to patients
with respect to the 10 days, four weeks, three months, six months,and 24 months follow-up.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04179201 -
Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
|
||
Completed |
NCT02563106 -
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
|
Phase 2 | |
Completed |
NCT00214461 -
Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers
|
Phase 1 | |
Completed |
NCT00314951 -
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
|
Phase 3 | |
Completed |
NCT00328263 -
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
|
Phase 3 | |
Completed |
NCT00127803 -
Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00350298 -
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
|
Phase 2 | |
Withdrawn |
NCT05077085 -
Bezlotoxumab Versus FMT for Multiple Recurrent CDI
|
Phase 4 | |
Completed |
NCT00446355 -
Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes
|
N/A | |
Terminated |
NCT00384527 -
Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
|
Phase 3 | |
Completed |
NCT00269399 -
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
|
Phase 3 | |
Completed |
NCT04026009 -
Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
|
Phase 1 | |
Recruiting |
NCT06277999 -
C.Difficile Observational Study
|
||
Completed |
NCT00468728 -
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
|
Phase 3 |